There is increasing evidence that immune mechanisms are involved in the pathogenesis of heart failure (HF). The relationship between neopterin and the risk of HF has yet to be investigated on a large scale. We assessed the relationship between neopterin, a novel marker of monocyte activation, and risk of hospitalization for HF.
Introduction
There is increasing evidence for the role of inflammation in the pathogenesis of heart failure (HF). 1 Notably, the cytokines tumour necrosis factor-a and interleukins 1 and 6 have been shown to be elevated both systemically 2 and locally 3 in association with decreased myocardial contractility 4 and with adverse cardiac remodelling. 5 Clinically, C-reactive protein levels have been shown to be an independent predictor of HF hospitalization after acute coronary syndromes (ACSs). 6, 7 Neopterin is a novel marker of macrophage/monocyte activation with a putative physiological role in enhancing macrophage cytotoxicity. Upon stimulation of macrophages with interferon-g, guanosine triphosphate (GTP) is enzymatically cleaved by GTP-cyclohydrolase to an intermediate product, 7,8-dihydroneopterin , which is then oxidized to form neopterin. Neopterin enhances macrophage † B.N. and K.K.R. contributed equally to this manuscript. cytotoxicity through its interactions with reactive oxygen, nitrogen, and chloride species. 8 In in vivo models of atherosclerosis, neopterin has been shown to promote oxidative stress-triggered apoptosis of vascular smooth muscle cells and to promote plaque growth. 9 As a clinical correlate, a recent analysis 10 has demonstrated an association between increased neopterin levels and future risk of recurrent acute coronary events after an ACS. While a pathophysiological relationship between neopterin and atherosclerosis has been demonstrated, its role in the inflammatory pathogenesis of HF has yet to be investigated on a large scale. We assessed the relationship between serum neopterin levels and risk of hospitalization for HF.
Methods

Patient population
The patient population is drawn from the PROVE-IT TIMI 22 trial, which has been previously described in detail. 11 Briefly, 4162 patients were enrolled after having been hospitalized for ACS in the preceding 10 days. Patients were eligible if they were in stable condition, had a total cholesterol level within 24 h after the index event of ,240 mg/dL (6.21 mmol/L) or ,200 mg/dL (5.18 mmol/L) if they were on prior lipid-lowering therapy. Patients were randomized 1:1 to receive either pravastatin 40 mg daily (standard therapy) or atorvastatin 80 mg daily (intensive therapy), and to gatifloxacin or placebo in a double-blinded fashion and were followed for a mean of 24 months.
Blood sampling and neopterin analysis
Details of blood sampling and assay methods have been reported previously. 11 Briefly blood samples were collected upon study entry (on average 6 days after ACS) in EDTA and frozen at 2208C or lower, and shipped on dry ice to the TIMI Biomarker Core Laboratory (Boston, MA, USA), where the specimens were stored at 2708C.
Neopterin assays was performed with one prior freeze-thaw cycle, using a commercially available ELISA kit (ALPCO Diagnostics, Windham, NH, USA) by technicians blinded to subjects' treatment arm, and using a robotic high-throughput platform (TECAN Genesis RSP 200/8). High-sensitivity testing for C-reactive protein, brain natriuretic protein (BNP), and lipids was performed as described previously.
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Clinical endpoints
The primary efficacy outcome for this analysis was the time from randomization until the first occurrence of hospitalization for HF. There was censoring after the first HF event, and the outcome is reported as incidence of HF hospitalization. Hospitalization for HF was categorized by the investigator as a hospitalization for new or worsening HF with evidence of pulmonary congestion on a chest radiograph and fulfillment of two of the following six criteria: rales in the midlung that do not clear with coughing; a left ventricular ejection fraction ,40%; a mean pulmonary capillary wedge pressure .18 mmHg and a cardiac index ,2.2 L/min*m 2 ; use of diuretics to treat pulmonary congestion in patients not previously taking diuretics or an increase in dose in patients taking diuretics chronically; need for intubation for hypoxia; or an oxygen saturation , 90% or an oxygen pressure (PaO 2 ) ,60 mmHg. We also assessed the composite endpoint of death from any cause or HF hospitalization. These endpoints were reported by the investigators at study sites via the Endpoint reporting mechanism of the trial, and as such, follow-up was as complete on all patients as it was for the primary endpoint.
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Statistical analyses
Neopterin was measured in 3946 patients at study entry. Differences in baseline characteristics across quartiles of neopterin at study entry were assessed using the x 2 test in the case of categorical variables and the Kruskal -Wallis test for continuous variables with P-values ,0.05 considered statistically significant. The event rates at 2 years across quartiles of neopterin were assessed and are presented as rates per 100 person-years of follow-up with differences across quartiles assessed using the log-rank test. The risk across increasing quartiles of neopterin was assessed using a test for linear trend. Sensitivity analyses were performed excluding individuals who had a recurrent ACS event or revascularization during the study and individuals who had a prior history of HF. As a linear trend in risk was observed between neopterin levels and risk of HF, we used a 1SD increment in neopterin (log transformed as it was not normally distributed) which reflects a 60% difference in levels, in univariate and multivariable Cox regression models to assess the continuous relationship between neopterin levels and HF. To determine whether the relationship between a 1SD log (neopterin) and HF varied across sub-groups, an interaction term between neopterin and the subgroup of interest was included in Cox models which also contained neopterin and the variable of interest. To assess whether the addition of neopterin to the known prognostic biomarker, BNP, improved risk prediction, the goodness of fit using the likelihood ratio test (LRT) was used. Briefly, each variable was added sequentially to a basic multivariable model to assess whether the added variable significantly improved risk prediction over and above the previous model. The LRT (2X the difference between the log likelihood of each model distributed as a x 2 statistic) was used to calculate the additional value that the factor added to the basic model with a test statistic of .3.84 considered significant (equivalent to a P-value of ,0.05 for 1 degree of freedom). For comparison, we also used the net reclassification improvement (NRI), the integrated discrimination improvement (IDI), and the C-statistic to assess the relative predictive ability of neopterin. 14 The P-value for C-statistic improvement was calculated based on the increment in the x 2 . The subset of patients used for the final risk prediction model included 3061 subjects in whom information on all variables of interest were available at study entry. All analyses were performed with the STATA version 9 (STATA Corp, College Station, TX, USA) and R version 2.9.1 (The R Foundation for Statistical Computing).
Results
Patient population
The population in this study has been described previously. 10 Briefly an average age of the subjects was 58, 22% were female, 18% had diabetes, 50% had hypertension, 37% were smokers, and roughly one-third had a diagnosis of ST-elevation myocardial infarction (STEMI), one-third had non-ST-elevation myocardial infarction (NSTEMI), and one-third had unstable angina (UA). When comparing the 3946 patients who had neopterin levels drawn with the 216 who did not, there were no differences in age .65, smoking status, diabetes, gender, or hypertension, but those with biomarkers had 2% lower prevalence of female gender and body mass index ,25. At baseline, neopterin levels ranged from 2 to 87.68 nmol/L, with a median of 9.65 nmol/L [inter-quartile range (IQR) 7.78-12.11 nmol/L, standard deviation 5.39 nmol/L], which was elevated compared with the mean + SD of 5.2 + 2.5 nmol/L for normal human subjects. 10 As shown in Table 1 , higher baseline levels of neopterin were also more likely to be associated with older age, prior history of hypertension and higher C-reactive protein levels. Higher neopterin levels were also less likely to be associated with smoking and use of percutaneous coronary intervention (PCI) for the index event and low-density lipoprotein (LDL)-C levels.
A multivariate linear regression analysis was performed using age, gender, ACS group, killip class, smoking, diabetes, hypertension, BNP, and C-reactive protein to help determine predictors of neopterin. Those factors that were significantly predictive were age (P , 0.001), smoking (P , 0.01), C-reactive protein (P , 0.001), hypertension (P , 0.001) and BNP (P , 0.001).
There was a weak, yet statistically significant Spearman's correlation between neopterin and C-reactive protein (r ¼ 0.25) and between neopterin and BNP (r ¼ 0.26), P , 0.0001 for both.
Relationship between neopterin and heart failure hospitalization
Among the 4162 patients enrolled in the TIMI 22-PROVE IT trial, 3,946 patients had neopterin measured at baseline. Of the 3946 patients with neopterin values measured, 144 had a censored HF event (3.7%), whereas of the 217 without neopterin measurements, 11 had censored HF event (5.1%). There was no statistically significant difference between the HF rates in these two groups (P ¼ 0.28). Increasing baseline neopterin levels were associated with increasing risk of HF hospitalization, with 0.66, 0.98, 2.09, and 3.97 HF hospitalizations per 100 person-years in Q1-4, respectively. Figure 1A , reflects the cumulative incidence of HF hospitalization overall in the cohort. This trend was also seen among both the intensive and standard therapy subjects ( Figure 1B and C, respectively). Compared with Q1 neopterin, the unadjusted hazard ratios (HRs) for HF hospitalization were 1.51 (95% CI 0.75-3.06), 3.22 (95% CI 1.72-6.02) and 6.13 (95% CI 3.39 -11.09), respectively ( Figure 2 , solid bars; P for trend ,0.0001).
To reduce the possibility that our observations were confounded by the association between neopterin and risk of acute coronary events, we conducted a sensitivity analysis by excluding any subjects who, after study entry, had a recurrent ACS event or coronary revascularization and a further analysis excluded individuals with a prior clinical history of HF, with similar findings (Figure 2 , checkered and striped bars, respectively), P for trend ,0.0001 for both.
In unadjusted analyses of the combined data set, the risk of HF per 1SD log (neopterin) was 1.70 (95% CI 1.51-1.92, P , 0.0001). This relationship was also seen when stratified by statin regimen, where the HR per 1SD log (neopterin) was 1.80 (95% CI 1.53-2.12, P , 0.0001) and 1.60 (1.33-1.93, P , 0.0001), respectively, for standard and intensive regimens. After excluding individuals with a recurrent ACS event or revascularization after study entry, the unadjusted HR per 1SD log (neopterin) was 1.63 (95% CI 1.35-1.96, P , 0.0001). We observed similar results after further excluding individuals with a prior history of HF where the HR per 1SD log (neopterin) was 1.65 (95% CI 1.34-2.04, P , 0.0001).
In addition, we calculated the sensitivity, specificity, positive predicted value, and negative predictive value for neopterin using its median as the cut point. For the endpoint of HF hospitalization, the values were 78.5, 50.8, 5.7, and 98.4%, respectively. For the combined endpoint of death or HF, the results were 72.6, 51.2, 8.7, and 96.7%, respectively.
Interaction between neopterin and other risk factors between a 1SD difference log (neopterin) and relevant baseline characteristics was assessed ( Table 2) . A 1SD (log neopterin) was significantly associated with an increased risk of HF in all subgroups including those with a low BNP level. Furthermore, there was a significant interaction between neopterin and hypertension (P ¼ 0.01) with neopterin more strongly associated with HF hospitalization among those patients without hypertension. There was no significant interaction between neopterin and gender, diabetes, smoking, LDL, C-reactive protein, or BNP. There was no interaction between neopterin and trial randomization arms of statin Figure 1 (A) Cumulative incidence of heart failure hospitalization by baseline quartile of neopterin (pooled data). P , 0.0001 log-rank test.
(B) Cumulative incidence of heart failure hospitalization by baseline quartile of neopterin (intensive statin therapy group). P , 0.0001 log-rank test. (C ) Cumulative incidence of heart failure hospitalization by baseline quartile of neopterin (standard statin therapy group). P , 0.0001 log-rank test.
Neopterin and HF regimen (P ¼ 0.35) or gatifloxacin vs. placebo (P ¼ 0.89) for the endpoint of HF hospitalization.
Comparison of elevated neopterin with other risk factors
As with most inflammatory markers, neopterin values fluctuate over time after ACS. Among our subjects, the time from index event to blood draw of baseline neopterin level varied from zero to 23 days (median 7 days, IQR 4 -9 days). There was no linear trend of neopterin when comparing tertiles of time from index event to baseline neopterin blood draw (0-4 days, 5-7 days, 8 -23 days), as mean neopterin levels were 10.38 (95% CI 5.88-18.84), 11.22 (6.39-20.41), and 11.06 (6.10-19.77), but there were differences across the three groups (ANOVA P ¼ Figure 3 . For the combined endpoint of death or HF, the similarly adjusted HR for 1SD log (neopterin) was 1.32 (95% CI 1.13-1.55; P , 0.001).
Incremental predictive value of neopterin
To determine whether the addition of a biomarker improved upon risk prediction when added to classical risk factors, we created a multivariable Cox model of HF risk and incrementally added in risk factors to determine the incremental predictive value ( Table 3) . A basic Cox model was created using the variables of age, gender, type of index ACS event, Killip class, renal function, diabetes, smoking, hypertension, statin regimen, and 1SD log (C-reactive protein). Using values at study entry, adding 1SD log (BNP) to the model yielded an improvement in the C-statistic from 0.748 to 0. Figure 3 Comparison of hazard ratios for heart failure hospitalization among various risk factors at study entry.
Neopterin and HF further increase in C-statistic to 0.784 (P ¼ 0.018) and of LRT statistic to 122 (P ¼ 0.005). Integrated discrimination improvement index was 0.025 (P ¼ 0.001). Net reclassification improvement index was 0.089 (P ¼ 0.377), indicating a non-significant trend towards improved reclassification. Results were similar for the combined endpoint of death or HF hospitalization ( Table 3) .
Discussion
We observed that higher neopterin levels (on average 7 days after ACS) were associated with increased risk of HF hospitalization over the next 2 years across a wide range of subgroups, including individuals with a low BNP. This linear relationship remained statistically significant after multivariable adjustment, where neopterin remained a strong predictor for HF. Similar results were obtained for the composite of death or HF, with a strong trend towards greater benefit from intensive statin therapy among individuals with higher neopterin levels. In three of our four risk prediction analyses, the addition of neopterin to BNP and other known HF-risk factors further improved risk prediction for HF hospitalization and death or HF by the same order of magnitude as BNP improved the basic model. While NRI analysis demonstrated improved reclassification of patients, this difference was not statistically significant for either the HF or death/HF endpoints. A possible explanation for this is that the IDI measures the incremental difference in the probability of an event and the direction of this difference, whereas the NRI measures only the direction of this difference. The IDI is a continuous measure of model improvement whereas the NRI is a categorical measure. Since categorical measures have less power than continuous measures, the IDI can demonstrate significant model improvement while the NRI does not.
Clinically neopterin levels correlate with the extent of coronary artery disease, 15 -17 and we have previously demonstrated the potential utility of neopterin in predicting recurrent coronary events, 10 suggesting that neopterin is a marker of a specific part of the inflammatory cascade (macrophage/monocyte activation) in atherogenesis. Our findings in this study clinical implicate neopterin and macrophage/monocyte activation in the pathogenesis of HF. Prior studies have demonstrated an inverse correlation between neopterin levels and left ventricular ejection fraction, 18 but our study is the first to demonstrate a relationship between neopterin levels and HF events. The putative mechanisms by which neopterin contributes to the pathogenesis of HF is that of promoting oxidative stress, as reactive oxygen species and oxidative stress are known to depress myocardial contractility. 19 More specifically, neopterin's interaction with the oxidant, peroxynitrite, may help to explain its role in the link between inflammation and HF. It is understood that pro-inflammatory cytokines depress cardiac function via the induction of the negative inotrope, inducible nitric oxide (NO) synthase. 20 Nitric oxide reacts with superoxide to form peroxynitrite, which has been shown in in-vitro rat heart models to induce contractile failure. 21 Neopterin has been shown in vitro to potentiate the ability of peroxynitrite to nitrate the amino acid tyrosine, causing cell damage at the molecular level. 22 However, in another study in which neopterin was directly infused into rat hearts impairing contractility, its effects were not alleviated by a NO synthase inhibitor, but only by n-acetylcysteine, a free radical scavenger, suggesting that neopterin's may have other negative inotropic effects that are independent of the NO/peroxynitrite pathway. 23 Mean serum neopterin in healthy subjects aged 19-75 years is 5.3 nmol/L with a standard deviation of 2.7, 24 thus the median levels of 9.67 nmol/L observed in this study are considerably higher. This may in part reflect a heightened state of immune activation among individuals with coronary disease, or a non-specific response to myonecrosis, or both. Evidence against the latter comes from our observation that there is little difference in neopterin levels across the spectrum of ACS from UA to ST-elevation MI, 10 which would suggest little relationship with myonecrosis.
Neopterin's low molecular weight, biological and chemical stability in serum and urine, and ease of measurement make it an attractive target for monitoring disease activity and response to therapy, as it has been investigated in the fields of infectious disease and transplant biology. 25 Furthermore our earlier work has demonstrated neopterin's within-person stability, as the two-year within-subject correlation between neopterin levels was r ¼ 0.60 (P , 0.0001).
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The strong association between neopterin levels and risk of HF hospitalization and its potential ability to improve risk prediction models which already include BNP, in particular excluding risk of HF, should help to encourage avenues of further investigation into the relationship between immune activation pathways and HF. To assess the potential aetiological relevance of neopterin levels to the progression in HF, the above findings should be studied in a population of subjects without a prior history of HF, and in the absence of prevalent coronary disease. As neopterin is secreted by monocytes, cell culture, and animal model experiments could be designed to further investigate the pathological role of monocyte activation in HF.
Limitations
There are several factors that merit consideration. First, it should be considered that the PROVE IT-TIMI 22 trial was not originally designed with HF hospitalization as a primary endpoint. Heart failure hospitalizations were physician-reported and the overall event rates of HF exacerbations were quite low. However, these hospitalizations were confirmed in the serious adverse event review process of the trial, and thus are a strong indication of development of significant HF. Second, this remains an observational study, and while we have attempted to control for confounding by multivariable adjustment, we cannot exclude the possibility of residual confounding. Anaemia has been shown to be associated with poor outcomes in HF patients. 26 Since haemoglobin and haematocrit were not routinely checked in the PROVE IT-TIMI 22 trial, anaemia could not be incorporated into our multivariable model. Finally, a significant proportion of HF is related to coronary ischaemia and while we have demonstrated significant associations between neopterin and HF after exclusion of subjects with recurrent ischaemic events and individuals with prior HF, we cannot exclude the possibility of confounding due to an association between neopterin and sub-clinical ischaemia. Finally the incremental predictive utility of neopterin in models which included C-reactive protein should be interpreted in the context of our prior work which has shown that the optimal time to measure C-reactive protein for prediction of HF is either very early after ACS (within 2 days) or very late (1 month after ACS). 
